(PRESS RELEASE) Vancouver, British Columbia–True Leaf Medicine International Ltd. (“True Leaf”) (CSE: MJ) (FSE: TLA) (OTCQB: TRLFF), a company involved in the hemp and cannabis-based product industry, has secured DTC eligibility for its common shares from The Depository Trust Company (DTC) effective October 10, 2017.
The DTC is a subsidiary of the Depository Trust & Clearing Corporation (DTCC), and manages the electronic clearing and settlement for the vast majority of publicly traded equities and other securities in the United States. Securities that are eligible to be electronically cleared and settled through DTC are considered “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.
“We are pleased to announce that we have obtained DTC eligibility,” commented True Leaf CEO Darcy Bomford. “Electronic trading is the standard in today’s financial markets, and becoming DTC eligible simplifies the process of trading and exchanging our common shares. We continue to make positive steps to grow True Leaf, and we would like to thank our agent, VStock Transfer, for its guidance through this process,” he added. “We will continue to update our shareholders on our progress.”
About True Leaf
True Leaf Medicine International Ltd., through its wholly owned subsidiary ‘True Leaf Pet’, has entered the global pet industry, forecast to reach $117 billion US in 2021, with a line of hemp-focused pet supplements in Canada, the United States and Europe. The company has also filed an application under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) to become a Canadian licensed producer of medical cannabis through its ‘True Leaf Medicine’ subsidiary. It has passed through the preliminary and enhanced screening process of Health Canada’s review and has recently received approval to build its facility.